Likeness Rx offers compounded GLP-1 plans with several payment terms. The public monthly figures are $139 for semaglutide and $199 for tirzepatide. The prepaid options lower the monthly equivalent, but a longer financial commitment should be considered separately from the ongoing clinical plan.
Ask about review, not just supply
Before choosing a longer term, ask how follow-up occurs, who reviews new concerns and how instructions are communicated if a prescription changes. The public price grid cannot establish those details for an individual patient. Do not assume paying for several months removes the need for further clinical assessment.
For context, the twelve-month advertised totals are $948 for semaglutide and $1,548 for tirzepatide, corresponding to $79 and $129 monthly equivalents. Those equivalents should always be read beside the upfront amount and selected term.
Keep billing and care separate
The GLP-1 page describes automatic renewal of the selected plan and an early first-refill charge. Ask for the dates and cancellation process. It also describes a refund when medication is not prescribed; that does not establish an unrestricted refund after treatment begins.
If a clinical question arises near a renewal, contact the appropriate clinical professional as well as the billing team when needed. An order's billing state does not answer whether a medicine should be used.
Confirm the actual preparation
These products are compounded, not FDA-approved. Ask why that choice fits your medical needs and which pharmacy handles the GLP-1 prescription. Do not transfer pharmacy information from Likeness's other product categories without confirmation.
Our #3 placement is promotional. We have not evaluated the safety of individual prescriptions, inspected the pharmacy or tested Likeness's response to a patient concern. Read this profile as a question guide with documented public terms.
Sources and limits
Checked October 5, 2026. Federal sources provide general guidance; provider pages describe advertised terms. These sources do not assess an individual patient's situation.
- Likeness Rx — GLP-1 plans and billingProvider offer
- FDA — concerns with unapproved GLP-1 drugsRegulator guidance